The role of secondary cytoreductive surgery for recurrent ovarian cancer
Authors:
- Mete GüngörMGMete Güngör
- Fırat OrtaçFOFırat Ortaç
- Macit ArvasMAMacit Arvas
- Derin KösebayDKDerin Kösebay
- Murat SönmezerMSMurat Sönmezer
- Kenan KöseKKKenan Köse
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 97 (1) , 74-79
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinomaCancer, 2000
- Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 PatientsGynecologic Oncology, 1998
- Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.International Journal of Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective studyCancer, 1995
- Ovarian carcinoma: value of CT in predicting success of debulking surgery.American Journal of Roentgenology, 1995
- Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical ResponseGynecologic Oncology, 1995
- Whole-Body Positron Emission Tomography with 2-[18F]-Fluoro-2-deoxy-D-glucose Can Detect Recurrent Ovarian CarcinomaGynecologic Oncology, 1993
- Secondary cytoreduction for ovarian cancer following cisplatin therapy.Journal of Clinical Oncology, 1993
- Secondary cytoreductive surgery for recurrent epithelial ovarian cancerGynecologic Oncology, 1989